21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
7 citations
,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
11 citations
,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
441 citations
,
May 2008 in “British Journal of Pharmacology” Anabolic steroids can build muscle and strength but have risks and need more research on their clinical benefits and side effects.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
14 citations
,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
2 citations
,
May 2025 in “Frontiers in Pharmacology” Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
6 citations
,
April 2004 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New progesterone-based compounds can block male hormones.
2 citations
,
September 1992 in “Steroids” New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.
59 citations
,
September 2003 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Epitestosterone may counteract testosterone's effects and has roles in body processes like prostate growth and hair distribution.
64 citations
,
January 1985 in “Clinical endocrinology” A combination of desogestrel and ethinyl oestradiol effectively reduces hair growth in hirsute women.
July 2025 in “Medical Science” Anabolic steroids and SARMs can cause serious liver damage.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
11 citations
,
November 2009 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
10 citations
,
October 2006 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are easier to use and target specific tissues to reduce side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
June 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” 17α-estradiol extends lifespan and improves metabolism in male mice through the estrogen receptor α.